BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 6:47:30 AM | Browse: 310 | Download: 775
Publication Name World Journal of Gastroenterology
Manuscript ID 101436
Country Spain
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Letter to the Editor
Article Title Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
Manuscript Source Invited Manuscript
All Author List Adrián Cortés-Martín and Julio Plaza-Diaz
ORCID
Author(s) ORCID Number
Julio Plaza-Diaz http://orcid.org/0000-0002-5171-9408
Funding Agency and Grant Number
Corresponding Author Julio Plaza-Diaz, PhD, School of Health Sciences, Universidad Internacional de La Rioja, Avenida de la Paz 137, Logrono 26006, La Rioja, Spain. julioramon.plaza@unir.net
Key Words Glucagon-like peptide 1 agonists; Liver diseases; Metabolic dysfunction-associated steatotic liver disease; Metabolic health; Pharmacotherapy; Diet; Gut microbiome; Physical exercise; Lifestyle; Non-alcoholic fatty liver disease
Core Tip This article comments on Soresi and Giannitrapani’s work concerning glucagon-like peptide 1 agonists as potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. The integration of dietary changes and regular physical exercise into treatment may improve patient outcomes. These lifestyle adjustments may reduce the reliance on pharmacological interventions and/or increase the effectiveness of existing treatments. Therefore, lifestyle factors should not be overlooked in the broader strategy for managing metabolic dysfunction-associated steatotic liver disease, since they complement medical therapies.
Publish Date 2024-12-30 06:47
Citation

Cortés-Martín A, Plaza-Diaz J. Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders. World J Gastroenterol 2025; 31(4): 101436

URL https://www.wjgnet.com/1007-9327/full/v31/i4/101436.htm
DOI https://dx.doi.org/10.3748/wjg.v31.i4.101436
Full Article (PDF) WJG-31-101436-with-cover.pdf